Scopus BioPharma
Transformational Therapeutics for Serious Diseases
Foreign StartupScopus BioPharma is a foreign startup in the Health Tech & Life Sciences sector, established in 2018. Transformational Therapeutics for Serious Diseases. Core technologies: Biologicals, Genes.
The company follows a B2B business model.
- ModelB2B
- Last RoundUndisclosed
What does Scopus BioPharma do?
Scopus BioPharma is a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. The companys lead development program, CO-sTiRNA, is a novel targeted immuno-oncology gene therapy for the treatment of multiple cancers. Its second lead development program, MRI-1867, is a peripherally restricted dual-action cannabinoid-1, or CB1, receptor inverse agonist and inhibitor of inducible nitric oxide synthase, or iNOS. Strategic partners of Scopus BioPharma include City of Hope, the National Institutes of Health, and Hebrew University, including their respective scientists, medical doctors, and other senior researchers.
What sector is Scopus BioPharma in?
Scopus BioPharma operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Genes. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.